Collaborations

  1. Cohen, L., Assaraf, Y.G. and Livney, Y.D. (2021) Novel Selectively Targeted Multifunctional Nanostructured Lipid Carriers for Prostate Cancer Treatment. Pharmaceutics. 14(1):88.
  2. Engelberg, S., Lin, Y., Assaraf, Y.G and Livney, Y.D. (2021) Targeted Nanoparticles Harboring Jasmine-Oil-Entrapped Paclitaxel for Elimination of Lung Cancer Cells. Int J Mol Sci. 22(3):1019.
  3. Soll, M., Chen, Q.C., Zhitomirsky, B., Lim, P.P., Termini, J., Gray, H.B., Assaraf, Y.G. and Gross, Z. (2020) Protein-coated corrole nanoparticles for the treatment of prostate cancer cells. Cell Death Discov. 6:67.
  4. Engelberg, S., Netzer, E., Assaraf, Y.G. and Livney, Y.D. (2019) Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo. Cell Death Dis. 10(10):702.
  5. Edelman, R., Assaraf, Y.G., Slavkin, A., Dolev, T., Shahar, T. and Livney, Y.D. (2019) Developing Body-Components-Based Theranostic Nanoparticles for Targeting Ovarian Cancer. Pharmaceutics. 11(5) pii: E216.
  6. Bar-Zeev, M., Kelmansky, D., Assaraf, Y.G. and Livney, Y.D. (2018) β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer. Eur J Pharm Biopharm. 133:240-249.
  7. Giovannetti, E., Zucali, P.A., Assaraf, Y.G., Funel, N., Gemelli, M., Stark, M. et. al. (2017) Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools. Ann Oncol.  28(11):2725-2732.
  8. Bar-Zeev, M., Livney, Y.D. and Assaraf, Y.G. (2017) Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.  Drug Resist Updat. 31:15-30.
  9. Edelman, R., Assaraf, Y.G., Levitzky, I., Shahar, T. and Livney, Y.D (2017)  Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy. Oncotarget. 8(15):24337-24353.
  10. Bar-Zeev, M., Assaraf, Y.G. and Livney, Y.D. (2016) β-casein nanovehicles for oral delivery of chemotherapeutic drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells. Oncotarget. 7(17):23322-34.
  11. Wojtuszkiewicz, A., Raz, S., Stark, M., Assaraf,Y.G. et. al. (2016) Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance. Int J Cancer. 138(7):1645-56.
  12. Verbrugge, S.E., Al, M., Assaraf, Y.G. et. al. (2015) Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR. Oncotarget. [Epub ahead of print]
  13. Wojtuszkiewicz, A., Peters, G.J., van Woerden, N.L., Dubbelman, B., Escherich, G., Schmiegelow, K., Sonneveld, E., Pieters, R., van de Ven, P.M., Jansen, G., Assaraf, Y.G., Kaspers, G.J. and Cloos, J. (2015) Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia. J Hematol Oncol 8:61.
  14. Porcelli, L., Giovannetti, E., Assaraf, Y.G., Jansen, G., Scheffer, G.L., Kathman, I., Azzariti, A., Paradiso, A. and Peters, G.J. (2014) The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib. Curr Drug Targets. 15(14):1322-30.
  15. Niewerth, D., van Meerloo, J., Jansen, G., Assaraf, Y.G., Hendrickx, T.C., Kirk, C.J., Anderl, J.L., Zweegman, S., Kaspers, G.J. and Cloos, J. (2014) Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924. Biochem Pharmacol. 86(1):12-9.
  16. Niewerth, D., Kaspers, G.J., Assaraf, Y.G., van Meerloo, J., Kirk, C.J., Anderl, J., Blank, J.L., van de Ven, P.M., Zweegman, S., Jansen, G. and Cloos, J. (2014) Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. J Hematol Oncol. 7(1):7.
  17. van der Heijden, J.W., Assaraf, Y.G., Gerards, A.H., Oerlemans, R., Lems, W.F., Scheper, R.J., Dijkmans, B.A. and Jansen, G. (2014) Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients. Scand J Rheumatol. 43(1):9-16.
  18. Niewerth, D., Franke, N.E., Jansen, G., Assaraf, Y.G., van Meerloo, J., Kirk, C.J., Degenhardt, J., Anderl, J., Schimmer, A.D., Zweegman, S., de Haas, V., Horton, T.M., Kaspers, G.J. and Cloos, J. (2013) Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica. 98(12):1896-904.
  19. Blits, M., Jansen, G., Assaraf, Y.G., van de Wiel, M.A., Lems, W.F., Nurmohamed, M.T., van Schaardenburg, D., Voskuyl, AE., Wolbink, G.J., Vosslamber, S. and Verweij, C.L. (2013) Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 65(11):2791-802.
  20. Verbrugge, S.E., Al, M., Assaraf, Y.G., Niewerth, D., van Meerloo, J., Cloos, J., van der Veer, M., Scheffer, G.L., Peters, G.J., Chan, E.T., Anderl, J.L., Kirk, C.J., Zweegman, S., Dijkmans, B.A., Lems, W.F., Scheper, R.J., de Gruijl, T.D. and Jansen, G. (2013) Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol. 2(1):2.
  21. Bachas, C., Schuurhuis, G.J., Assaraf, Y.G., Kwidama, Z.J., Kelder, A., Wouters, F., Snel, A.N., Kaspers, G.J. and Cloos, J. (2012) The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia. 26(6):1313-20.
  22. Verbrugge, S.E., Assaraf, Y.G., Dijkmans, B.A., Scheffer, G.L., Al, M., den Uyl, D., Oerlemans, R., Chan, E.T., Kirk, C.J., Peters, G.J., van der Heijden, J.W., de Gruijl, T.D., Scheper, R.J. and Jansen, G. (2012) Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther. 341(1):174-82.
  23. Franke, N.E., Niewerth, D., Assaraf, Y.G., van Meerloo, J., Vojtekova, K., van Zantwijk, C.H., Zweegman, S., Chan, E.T., Kirk, C.J., Geerke, D.P., Schimmer, A.D., Kaspers, G.J., Jansen, G. and Cloos, J. (2012) Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia. 26(4):757-68.
  24. Shapira, A., Davidson, I., Avni, N., Assaraf, Y.G. and Livney, Y.D. (2012) Beta-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: stability, target-activated release and cytotoxicity. Eur J Pharm Biopharm. 80(2):298-305.
  25. de Wilt, L.H., Jansen, G., Assaraf, Y.G., van Meerloo, J., Cloos, J., Schimmer, A.D., Chan, E.T., Kirk, C.J., Peters, G.J. and Kruyt, F.A. (2012) Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem Pharmacol. 83(2):207-17.
  26. Gotink, K.J., Broxterman, H.J., Labots, M., de Haas, R.R., Dekker, H., Honeywell, R.J., Rudek, M.A., Beerepoot, L.V., Musters, R.J., Jansen, G., Griffioen, A.W., Assaraf, Y.G., Pili, R., Peters, G.J. and Verheul, H.M. (2011) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res. 17(23):7337-46.
  27. Giovannetti, E., Zucali, P.A., Assaraf, Y.G., Leon, L.G., Smid, K., Alecci, C., Giancola, F., Destro, A., Gianoncelli, L., Lorenzi, E., Roncalli, M., Santoro, A. and Peters, G.J. (2011) Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer. 105(10):1542-53.
  28. Lemos, C., Giovannetti, E., Zucali, P.A., Assaraf, Y.G., Scheffer, G.L., van der Straaten, T., D’Incecco, A., Falcone, A., Guchelaar, H.J., Danesi, R., Santoro, A., Giaccone, G., Tibaldi, C. and Peters, G.J. (2011) Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics. 12(2):159-70.
  29. Shapira, A., Assaraf, Y.G., Epstein, D. and Livney, Y.D. (2010) Beta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assembly. Pharm Res. 27(10):2175-86.
  30. Bachas, C., Schuurhuis, G.J., Hollink, I.H., Kwidama, Z.J., Goemans, B.F., Zwaan, C.M., van den Heuvel-Eibrink, M.M., de Bont, E.S., Reinhardt, D., Creutzig, U., de Haas, V., Assaraf, Y.G., Kaspers, G.J. and Cloos, J. (2010) High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood. 116(15):2752-8.
  31. Zucali, P.A., Giovannetti, E., Assaraf, Y.G., Ceresoli, G.L., Peters, G.J. and Santoro, A. (2010) New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma. Ann Oncol. 21(7):1560-1.
  32. Shapira, A., Markman, G., Assaraf, Y.G. and Livney, Y.D. (2010) Beta-casein-based nanovehicles for oral delivery of chemotherapeutic drugs: drug-protein interactions and mitoxantrone loading capacity. Nanomedicine. 6(4):547-55.
  33. Pinhassi, R.I., Assaraf, Y.G., Farber, S., Stark, M., Ickowicz, D., Drori, S., Domb, A.J. and Livney, Y.D. (2009) Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules. 11(1):294-303.
  34. Beretta, G.L., Benedetti, V., Cossa, G., Assaraf, Y.G., Bram, E., Gatti, L., Corna, E., Carenini, N., Colangelo, D., Howell, S.B., Zunino, F. and Perego, P. (2010) Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem Pharmacol. 79(8):1108-17.
  35. Shapira, A., Assaraf, Y.G. and Livney, Y.D. (2010) Beta-casein nanovehicles for oral delivery of chemotherapeutic drugs. Nanomedicine. 6(1):119-26.
  36. Held-Kuznetsov, V., Rotem, S., Assaraf, Y.G. and Mor, A. (2009) Host-defense peptide mimicry for novel antitumor agents. FASEB J. 23(12):4299-307.
  37. Etgar, L., Leitus, G., Fradkin, L., Assaraf, Y.G., Tannenbaum, R. and Lifshitz, E. (2009) Optical and magnetic properties of conjugate structures of PbSe quantum dots and gamma-Fe(2)O(3) nanoparticles. Chemphyschem. 10(13):2235-41.
  38. Fotoohi, A.K., Assaraf, Y.G., Moshfegh, A., Hashemi, J., Jansen, G., Peters, G.J., Larsson, C. and Albertioni, F. (2009) Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol.77(8):1410-7.
  39. van der Heijden, J.W., Oerlemans, R., Tak, P.P., Assaraf, Y.G., Kraan, M.C., Scheffer, G.L., van der Laken, C.J., Lems, W.F., Scheper, R.J., Dijkmans, B.A. and Jansen, G. (2009) Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide.Arthritis Rheum. 60: 669-677.
  40. Oerlemans, R., Franke, N.E., Assaraf, Y.G., Cloos, J., van Zantwijk, I., Berkers, C.R., Scheffer, G.L., Debipersad, K., Vojtekova, K., Lemos, C., van der Heijden, J.W., Ylstra, B., Peters, G.J., Kaspers, G.L., Dijkmans, B.A., Scheper, R.J. and Jansen, G. (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.  Blood. 112: 2489-2499.
  41. Oerlemans, R., Vink, J., Dijkmans, B.A., Assaraf, Y.G., van Miltenburg, M., van der Heijden, J., Ifergan, I., Lems, W.F., Scheper, R.J., Kaspers, G.J., Cloos, J. and Jansen, G. (2007) Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis. Ann Rheum Dis. 66: 1289-1295.
  42. Oerlemans, R., van der Heijden, J., Vink, J., Dijkmans, B.A., Kaspers, G.J., Lems, W.F., Scheffer, G.L., Ifergan, I., Scheper, R.J., Cloos, J., Assaraf, Y.G., and Jansen, G. (2006) Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis Rheum. 54: 557-568.
  43. Assaraf, Y.G., Ifergan, I., Kadry, W.N., and Pinter, R.Y. (2006) Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets. J Theor Biol. 240: 637-647.
  44. Binyamin, L., Assaraf, Y.G., and Reiter, Y. (2005) Probing ATP-dependent conformational changes in the multidrug resistance protein 1 (MRP1/ABCC1) in live tumor cells with a novel recombinant single chain Fv antibody targeted to the extracellular N-terminus. Int J Cancer. 116: 703-709.
  45. Fotoohi, K., Jansen, G., Assaraf, Y.G., Rothem, L., Stark, M., Kathmann, I., Gregorczyk, J., Peters, G.J., and Albertioni, F. (2004) Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy. Blood 104: 4194-4201.
  46. de Bruin, M., Peters, G.J., Oerlemans, R., Assaraf, Y.G., Masterson, A., Adema, A.D., Dijkmans, B.A.C., Pinedo, H.M., and Jansen, G. and (2004) Sulphasalazine down-regulates the expression of the angiogenic factors, platelet-derived endothelial cell growth factor/ thymidine phosphorylase and interleukin 8 in human monocytic-macrophage THP-1 and U937 cells. Mol. Pharmacol. 66: 1054-1060.
  47. Jansen, G., van der Heijden, J., Oerlemans, R., Lems, W.F., Ifergan, I., Scheper, R.J., Assaraf, Y.G., Dijkmans, B.A.C. (2004) Sulphasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum. 50: 2130-2139.
  48. Binyamin, L., Assaraf, Y.G., Haus-Cohen, M., Stark, M., and Reiter, Y. (2004) Targeting an extracellular epitope of the human multidrug resistance protein 1 (MRP1) in malignant cells with a novel recombinant single-chain Fv antibody. Int. J. Cancer 110: 882-890.
  49. Hooijberg, J.H., Jansen, G., Assaraf, Y.G., Kathmann, I., Pieters, R., Laan, A.C., Veerman, A.J.P., Kaspers, G.J.L., and Peters, G.J. (2004) Folate concentration dependent transport activity of the multidrug resistance protein 1 (ABCC1). Biochem. Pharmacol. 67: 1541-1548.
  50. Haus-Cohen, M., Assaraf, Y.G., Binyamin, L., Benhar, I., and Reiter, Y. (2004) Disruption of P-glycoprotein anticancer drug efflux activity by a small recombinant single-chain Fv antibody fragment targeted to an extracellular epitope. Int. J. Cancer 109: 750-758.
  51. van der Heijden, J., de Jong, M., Dijkmans, B.A.C., Lems, W.F., Oerlemans, R., Kathmann, I., Scheffer, G.L., Scheper, R.J., Assaraf, Y.G., Jansen, G. (2004). Acquired resistance of human T cells to sulphasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann. Rheum. Dis. 63: 131-137.
  52. Baron, D., Assaraf, Y.G., Drori, S., and Aronheim, A. (2003) Disruption of transport activity in a D93H mutant thiamine transporter 1 from a Rogers syndrome family. Eur. J. Biochem. 270: 4469-4477.
  53. Hooijberg, J-H., Peters, G.J., Assaraf, Y.G., Kathmann, I.A., Priest, D.G., Bunni, M.A., Kool, M., Kaspers, G.J.L., Veerman, A.J.P., Caspers, G.J.L., and Jansen, G. (2003). The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem. Pharmacol. 65: 765-771.
  54. Assaraf, Y.G., Rothem, L., Hooijberg, J.H., Stark, M., Ifergan, I., Kathmann, I.A., Dijkmans, B.A.C., Peters, G.J., and Jansen, G. (2003)  Loss of multidrug resistance protein 1 (MRP1) expression and folate efflux activity results in a highly concentrative transport of folates in human leukemia cells. J. Biol. Chem. 278: 6680-6686.